A therapeutic approach for female, relapsing genital lichen sclerosus: a single-center study

Patsatsi, Aikaterini; Kyriakou, Aikaterini; Vavilis, Dimitrios; Mantas, Athanasios; Patsialas, Christos; Sotiriadis, Dimitrios

doi:10.3109/09546634.2012.751086

Cited by 5 publications

(4 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is recommended that topical emollients be administered a few times per day [29]. Daily application of emollients or topical vitamin E as a maintenance therapy in VLS seems to postpone the relapse but is less effective than topical glucocorticosteroids and calcineurin inhibitors [70,71]. Additionally, selecting silk underwear might be of support because it alleviates pain and itching [8].…”

Section: Adipose-derived Stem Cells and Platelet-rich Plasmamentioning

confidence: 99%

“…kilka razy dziennie [29]. Przypuszcza się, że codzienne aplikowanie emolientów lub miejscowe leczenie witaminą E w ramach terapii podtrzymującej u pacjentek z VLS opóźnia nawrót choroby, choć jest to opcja mniej skuteczna w porównaniu z miejscowo stosowanymi glikokortykosteroidami i inhibitorami kalcyneuryny [70,71]. Pomocne może być również noszenie bielizny wykonanej z jedwabiu, która łagodzi dolegliwości bólowe i świąd [8].…”

Section: Conflict Of Interestunclassified

See 1 more Smart Citation

Lichen sclerosus

Jabłonowska¹,

Woźniacka²,

Żebrowska³

2021

View full text Add to dashboard Cite

Lichen sclerosus is a chronic skin condition with extragenital and/or genital involvement. The disease may develop in women and men of any age, but most frequently affects postmenopausal women. The aetiology of lichen sclerosus remains unknown. Genetic, infectious, environmental, autoimmune, and hormonal factors are presumed to influence its development. In most cases, lesions are located in the anogenital area. It is associated with sexual morbidity and is associated with an increased risk of cancerogenesis. The first-line treatment of lichen sclerosus includes ultrapotent corticosteroid ointments. Topical calcineurin inhibitors are considered second choice treatment. In recalcitrant cases alternative treatment methods (phototherapy and photochemotherapy, oral retinoids, methotrexate, cyclosporine, photodynamic therapy, adipose-derived stem cells and platelet-rich plasma, surgical management) are used. Because of a possible 3-8% risk of malignant transformation of genital lichen sclerosus to squamous cell carcinoma, early diagnosis is required, and long-term follow-up is recommended.streszczenie Liszaj twardzinowy jest przewlekłą chorobą skóry. Występuje w postaci pozagenitalnej i/lub genitalnej. Choroba jest stwierdzana u kobiet i mężczyzn niezależnie od wieku, ale najczęściej dotyczy kobiet w okresie po menopauzie. Etiologia liszaja twardzinowego jest nieznana. Przypuszcza się, że w jego rozwoju pewną rolę odgrywają czynniki genetyczne, zakaźne, środowiskowe, autoimmunologiczne oraz hormonalne. W większości przypadków zmiany są umiejscowione w okolicy anogenitalnej, co wiąże się z zaburzeniem funkcji seksualnych i możliwością kancerogenezy. W terapii pierwszego wyboru u pacjentów z liszajem twardzinowym stosuje się bardzo silnie działające maści z glikokortykosteroidami. Terapia drugiego wyboru opiera się na miejscowych inhibitorach kalcyneuryny. W przypadkach opornych na leczenie stosowane są alternatywne metody terapeutyczne (fototerapia i fotochemioterapia, doustne retinoidy, metotreksat, cyklosporyna, terapia fotodynamiczna, leczenie komórkami macierzystymi pochodzenia tłuszczowego i osoczem bogatopłytkowym, a także zabiegi chirurgiczne). Ze względu na ryzyko złośliwej przemiany postaci genitalnej liszaja twardzinowego w raka płaskonabłonkowego (3-8% przypadków) konieczne jest wczesne rozpoznanie i długoterminowa obserwacja pacjenta.

show abstract

Section: Adipose-derived Stem Cells and Platelet-rich Plasmamentioning

confidence: 99%

Section: Conflict Of Interestunclassified

Lichen sclerosus

Jabłonowska¹,

Woźniacka²,

Żebrowska³

2021

View full text Add to dashboard Cite

show abstract

“…The steroid ointment can be very effective, some patients receive symptomatic relief or even temporary disease remission [1]. Second line treatment for patients who do not respond to Clobetasol have not shown to be as effective as first line treatment options [19]. These treatments include topical calcineurin inhibitors such as tacrolimus, either alone or in addition to the topical steroid [20].…”

Section: Introductionmentioning

confidence: 99%

Autologous Adipose-Derived Stem Cell Treatment for Women with Genital Lichen Sclerosus

Newman¹,

Rogowski²,

Newman³

et al. 2018

Gynecol Reprod Health

View full text Add to dashboard Cite

Background: Lichen Sclerosus (LS) is a debilitating disease that causes chronic inflammation most commonly noted in the anogenital region. Many patients with genital Lichen Sclerosus report unsuccessful results with standard treatment options including steroids, calcineurin inhibitors, and/or hormone therapy. These patients presented to our clinic seeking autologous adipose-derived stem cell treatment (AASCT). Methods: Data was collected through questionnaires regarding disease symptoms on a daily basis and quality of life indicators. Questionnaires were completed by patients before and three months post AASCT. One hundred and eleven consecutive women who presented to our clinic from 2011 to 2015 with symptomatic, clinically apparent or biopsy proven genital Lichen Sclerosus were given the questionnaires and 100 of these patients completed both questionnaires. Results: The questionnaires were statistically analyzed to compare improvement in symptoms before and three months after AASCT. The improvement in every symptom was statistically significant (P<0.001). These symptoms included: itching, burning, pain, discomfort, blisters, ulcers, fusing, tearing, and fissures. Improvement in ability to carry out daily activities (such as voiding, bowel movements, exercising, intercourse, and wearing pants/ underwear) also showed substantial improvement that was statistically significant (P<0.001). Conclusion: Given the results, we can confidently say that AASCT is a promising new alternative treatment for patients suffering from Lichen Sclerosus. Additional AASCT may provide patients with further improvement in their symptoms. At present, long term follow-up is being conducted by our clinic to evaluate the course of the disease and the duration of improvements achieved from this treatment.

show abstract

“…2 nd Dermatology Department,2 1 st Department of Obstetrics and Gynecology, 3 Department of Urology, Aristotle University School of Medicine, Plagiari PO…”

mentioning

confidence: 99%

Circulating Anti-BP180 NC16a and Anti-BP230 Autoantibodies in Patients with Genital Lichen Sclerosus Do Not Correlate with Disease Activity and Pruritus

Patsatsi¹,

Kyriakou²,

Mantas³

et al. 2014

Acta Derm Venerol

View full text Add to dashboard Cite

A therapeutic approach for female, relapsing genital lichen sclerosus: a single-center study

Abstract: MPA 0.1% is effective in relapsing female GLS. MPA 0.1% and tacrolimus have equal efficacy in preventing relapses.

Cited by 5 publications

References 11 publications

Lichen sclerosus

Lichen sclerosus

Autologous Adipose-Derived Stem Cell Treatment for Women with Genital Lichen Sclerosus

Circulating Anti-BP180 NC16a and Anti-BP230 Autoantibodies in Patients with Genital Lichen Sclerosus Do Not Correlate with Disease Activity and Pruritus

Contact Info

Product

Resources

About